Intellia Therapeutics, Inc. (38I.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. John M. Leonard M.D. | President, CEO & Director | 989.07k | -- | 1957 |
| Dr. Laura Sepp-Lorenzino Ph.D. | Special Advisor to the Chief Executive Officer | 636.49k | -- | 1965 |
| Dr. David Lebwohl M.D. | Executive VP & Chief Medical Officer | 624.71k | -- | 1955 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | -- | -- | 1986 |
| Dr. Andrew May Ph.D. | Founder and Member of Scientific Advisor Board | -- | -- | -- |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | -- | -- | 1964 |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | -- | -- | -- |
| Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder & Member of Scientific Advisor Board | -- | -- | -- |
| Prof. Luciano Marraffini Ph.D. | Founder & Member of Scientific Advisor Board | -- | -- | -- |
| Mr. Erik J. Sontheimer Ph.D. | Founder & Member of Scientific Advisor Board | -- | -- | -- |
Intellia Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 403
Description
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Intellia Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available